Positive predictive value (PPV), sensitivity and specificity | ||
Group 1. Women with deviations of immune reactivity in one or more parameters of ELI-P-Complex (n = 2153) | 257 + 1763 | 133 |
Group 2. Women with normal results of ELI-P-Complex (n = 1816) | 148 | 1403 + 145 + 120 |
Relative risk (RR) for pregnancy complications | ||
Group 1. Women with deviations of immune reactivity in one or more parameters of ELI-P-Complex (n = 2153) | 257 + 1763 | 28 + 105 |
Group 2. Women with normal results of ELI-P-Complex (n = 1816) | 127 + 11 + 8 | 1403 + 145 + 122 |
Relative risk (RR) for adverse pregnancy outcome | ||
Group 1. Women with deviations of immune reactivity in one or more parameters of ELI-P-Complex (n = 2153) | 120 + 753 | 165 + 1115 |
Group 2. Women with normal results of ELI-P-Complex (n = 1816) | 108 + 9 + 8 | 1422 + 147 + 122 |
Relative risk (RR) for newborns health state | ||
Group 1. Women with deviations of immune reactivity in one or more parameters of ELI-P-Complex (n = 1549) | 714 + 109 | 620 + 106 |
Group 2. Women with normal results of ELI-P-Complex (n = 1663) | 87 + 12 + 12 | 1297 + 140 + 115 |